Barrington John Albert Furr

Avesthagen Ltd. provides personalized healthcare through convergence of food, pharma and population genetics. It offers genome analysis, transcriptome analysis, metabolome analysis and lead optimization, and recombinant protein expression services, as well as engages in the generation of stable mammalian cell lines over-expressing a recombinant protein, development of product specific bioassays, and design of novel animal component free production media. The company was founded by Villoo Morwala Zareer Patell on April 20, 1998 and is headquartered in Bangalore, India.

Evgen Ltd. develops novel glucosinolate based products for the prevention and treatment of human disease. It engages in the clinical stage drug development that lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. Its activities also include carrying out preclinical work in multiple sclerosis and has a clinical interest in prostate cancer. The firm holds proprietary technology that enables sulforaphane to be synthesized and then subsequently stabilized for pharmaceutical application. The company was founded by Dr. Stephen Franklin on October 18, 2007 and is headquartered in Liverpool, the United Kingdom.

Almirall Ltd. is an international pharmaceutical company based on innovation and committed to health, headquartered in Barcelona, Spain. In Almirall they research, develop, produce and market proprietary R&D medicines and those under licence with the aim of improving people's health and wellbeing. They devote big human and economic resources to constant research into new drugs and to obtaining effective and safe products against discomfort and disease.

Abingworth Management Ltd. operates as an investment firm with interests in the life sciences and healthcare sectors. It offers services for businesses in all stages of company development, including early and late-stage venture financing, growth equity, and public companies. The company was founded in 1973 and is headquartered in London, the United Kingdom.

Astex Therapeutics Ltd. engages in the provision of drug discovery and development activities. Its proprietary fragment-based drug discovery platform, Pyramid, delivers drug leads on therapeutic targets and disease areas.The company was founded by Harren Jhotin, Roberto Solari, Stephen W. Bunting, Christopher Abell, and Thomas L. Blundell in 1999 and is headquartered in Cambridge, the United Kingdom.